Refine
Year of publication
Document Type
- Article (151)
- Preprint (113)
- Doctoral Thesis (1)
Language
- English (265)
Has Fulltext
- yes (265)
Is part of the Bibliography
- no (265)
Keywords
- LHC (8)
- ALICE experiment (4)
- ALICE (3)
- Hadron-Hadron Scattering (3)
- Heavy Ions (3)
- pp collisions (3)
- Beauty production (2)
- Charm physics (2)
- RHIC (2)
- Single electrons (2)
Institute
- Physik (263)
- Frankfurt Institute for Advanced Studies (FIAS) (182)
- Informatik (175)
- Biowissenschaften (1)
- Hochschulrechenzentrum (1)
We report first results on elliptic flow of identified particles at midrapidity in Au+Au collisions at sqrt[sNN] = 130 GeV using the STAR TPC at RHIC. The elliptic flow as a function of transverse momentum and centrality differs significantly for particles of different masses. This dependence can be accounted for in hydrodynamic models, indicating that the system created shows a behavior consistent with collective hydrodynamical flow. The fit to the data with a simple model gives information on the temperature and flow velocities at freeze-out.
The minimum-bias multiplicity distribution and the transverse momentum and pseudorapidity distributions for central collisions have been measured for negative hadrons ( h-) in Au+Au interactions at sqrt[sNN] = 130 GeV. The multiplicity density at midrapidity for the 5% most central interactions is dNh-/d eta | eta = 0 = 280±1(stat)±20(syst), an increase per participant of 38% relative to pp-bar collisions at the same energy. The mean transverse momentum is 0.508±0.012 GeV/c and is larger than in central Pb+Pb collisions at lower energies. The scaling of the h- yield per participant is a strong function of pperp. The pseudorapidity distribution is almost constant within | eta |<1.
We report the first measurement of inclusive antiproton production at midrapidity in Au+Au collisions at sqrt[sNN] = 130 GeV by the STAR experiment at RHIC. The antiproton transverse mass distributions in the measured transverse momentum range of 0.25<pperp<0.95 GeV/c are found to fall less steeply for more central collisions. The extrapolated antiproton rapidity density is found to scale approximately with the negative hadron multiplicity density.
We report results on the ratio of midrapidity antiproton-to-proton yields in Au+Au collisions at sqrt[sNN] = 130 GeV per nucleon pair as measured by the STAR experiment at RHIC. Within the rapidity and transverse momentum range of | y|<0.5 and 0.4<pt<1.0 GeV/c, the ratio is essentially independent of either transverse momentum or rapidity, with an average of 0.65±0.01(stat)±0.07(syst) for minimum bias collisions. Within errors, no strong centrality dependence is observed. The results indicate that at this RHIC energy, although the p-p-bar pair production becomes important at midrapidity, a significant excess of baryons over antibaryons is still present.
Glucose homeostasis is tightly regulated by insulin production from ß-cells and glucagon production from α-cells. Changes in the balance of these hormones lead to Diabetes Mellitus (DM), which is foreseen to be the 7th leading cause of death by 2030, warranting a high demand to identify new therapeutics. DM is characterized by a reduction in ß-cell mass and reduced insulin production from ß-cells. α-cell development and fate mainly depend on the activity of the homeodomain-containing transcription factor Aristaless related homeobox (Arx). Conditional loss- of- function of Arx in α-cells leads to their conversion into functional insulin-producing ß-cells and thus an expansion of ß-cell mass. Therefore, inhibition of Arx is an interesting target for the expansion of ß-cells. The zebrafish model provides a fast, cost-effective and reliable translational platform for drug discovery in an in vivo setting. Here, we screened ~6217 small molecules on a transgenic zebrafish line (TgBAC(arxa:Luc2)) in which the arx promoter drives the expression of the luciferase gene which allows a sensitive and quantitative readout of promoter activity. Small molecule screening allowed us to identify 36 candidate repressors of arxa promoter activity. Furthermore, we started to validate these candidates in other assays. Preliminary results showed that DMAT (a potent CK2 inhibitor) and CNS-1102 (NMDA receptor inhibitor) increase functional ß-cell regeneration. By lineage tracing α-cells during ß-cell regeneration, we could show that both DMAT and CNS-1102 promote α- to ß-cell transdifferentiation. Here, we propose that Casein kinase II and NMDA receptor as potential molecular targets that could be exploited for the treatment of diabetes by generating functional beta-cells from the non-beta-cell progenitor, particularly alpha-cells in situ.